Recently, the QUANTUM-R trial, which was designed specifically for refractory or relapsed (R/R) FLT3-ITD AML patients, demonstrated the greater efficacy of quizartinib as a single agent versus the control arm [11]. Here, FLT3 is linked to acute myeloid leukemia.